Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256451 · ClinicalTrials.gov registry record · Phase 4
Endophenotype for Alcohol Misuse in Healthy Minority Populations
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00256451: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT00256451 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00256451, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with naltrexone, a medication that blocks some of the effects of alcohol and is approved for the treatment of alcoholism. The investigators are conducting this study on those of African descent because there is almost no research focused on this group and the association with genetics. The investigators seek to enroll 40 people in the study. Participation will consist of 4 different alcohol challenge sessions in a cross over design. Each session will be separated by at least 10 days. In total, there will be four challenge sessions.
Interventions
- DRUG placebo
- DRUG Naltrexone
- OTHER alcohol
- OTHER Sham alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00256451
The ClinicalTrials.gov registry entry for NCT00256451 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00256451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00256451 about?
NCT00256451 is a clinical study titled "Endophenotype for Alcohol Misuse in Healthy Minority Populations". The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with naltrexone, a medication that blocks some of the effects of alcohol and is approv...
What is the current status of trial NCT00256451?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2005-11. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00256451?
The interventions under investigation include: placebo (DRUG), Naltrexone (DRUG), alcohol (OTHER), Sham alcohol (OTHER).
Who is sponsoring clinical trial NCT00256451?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.